NeuroVision Announces A $15 Million Series C Financing With A First Close Of $11.2 Million

 NeuroVision Imaging Inc. has announced a Series C financing round of $15 million with an initial close of $11.2 million. The round is led by Wildcat Capital Management with funding from several new investment groups.

The financing provides support for NeuroVision as it seeks validation and regulatory approval for its breakthrough, low-cost, noninvasive, eye imaging system for measuring retinal autofluorescence that can detect amyloid beta (Aβ) plaque in the eye. Aβ plaque deposits in the brain are a hallmark sign of Alzheimer's disease, and histological evidence shows that Aβ plaque also accumulates in the retina, the photoreceptor and nerve complex at the rear of the eye.

In addition to Wildcat Capital Management, participants in this round are Johnson & Johnson Innovation – JJDC Inc. (JJDC), Nikon-SBI Innovation Fund, Whittier Ventures LLC, and VSP Global®.